Abstract
Tetrandrine (Tet) is a potent inhibitor of Ebola virus replication by blocking NAADP-dependent calcium release through endolysosomal two-pore channels (TPCs) and a moderately potent anti-tumor agent. Using a clickable photoaffinity probe, we identify lysosomal integral membrane protein-2 (LIMP-2) as a direct target of Tet and a key regulator of this calcium signaling. Tet binds LIMP-2's ectodomain, inhibiting lysosomal cholesterol and sphingosine transport, which alters lipid metabolism. Tet treatment and LIMP-2 depletion inhibit NAADP-dependent calcium release, reversible by removing lysosomal cholesterol and sphingosine. Sphingosine triggers lysosomal calcium release via TPCs and restores this signaling in Tet-treated or LIMP-2-deficient cells, revealing a LIMP-2-regulated, sphingosine-dependent lysosomal calcium pathway. At higher doses, Tet induces apoptosis through unfolded protein response activation independently of LIMP-2. These findings highlight Tet as a LIMP-2 inhibitor, elucidate its role in calcium signaling and cell death, and suggest therapeutic potential for Tet and LIMP-2 inhibitors in antiviral treatments.
Introduction
Tetrandrine (Tet), a bisbenzylisoquinoline alkaloid derived from the plant Stephania tetrandra, has long been recognized for its pharmacological potential, particularly as a potent inhibitor of Ebola virus entry and a moderately effective anti-tumor agent. For years, the scientific consensus was that Tetrandrine directly inhibited Two-Pore Channels (TPCs), the primary calcium release channels in lysosomes. However, direct evidence of Tet binding to TPCs remained elusive. This study identifies the "missing link" in this pathway: the lysosomal transporter LIMP-2. By characterizing the interaction between Tet and LIMP-2, researchers have uncovered a novel mechanism where lipid transport—specifically of sphingosine—regulates the calcium signaling required for viral entry.
Methodology
To identify the direct molecular target of Tetrandrine, the researchers utilized a chemical proteomics approach centered on a custom-designed probe, AD-Tet. This probe incorporates a diazirine group for UV-activated photo-crosslinking and an alkyne handle for subsequent "click" chemistry, allowing for the attachment of fluorescent tags or affinity beads for purification.
Key experimental steps included:
- SILAC-MS: Stable Isotope Labeling by Amino Acids in Cell Culture (SILAC) combined with Mass Spectrometry was used to identify proteins that specifically crosslinked with AD-Tet.
- Multi-Omics Analysis: Transcriptomics, lipidomics, and live-cell calcium imaging were employed to assess the functional consequences of Tet binding.
- Binding Assays: Microscale Thermophoresis (MST) and computational docking were used to quantify the binding affinity between Tet and the identified target, LIMP-2.
Results
Identification of LIMP-2 as the Direct Target
Proteomic screening identified Lysosomal Integral Membrane Protein-2 (LIMP-2) as the primary target of Tetrandrine. MST assays confirmed that Tet binds to the luminal domain of LIMP-2 with a dissociation constant ($K_d$) of approximately 241 μM. Importantly, imaging studies using the AD-Tet probe demonstrated high colocalization with lysosomal markers (Pearson’s correlation of 0.8), and this labeling could be competitively inhibited by excess native Tetrandrine, confirming the specificity of the interaction.
Mechanism of Calcium Signaling Inhibition
LIMP-2 is a known transporter of cholesterol and sphingosine out of the lysosome. The study revealed that Tetrandrine blocks this transport function, leading to the accumulation of these lipids within the lysosome. Crucially, the researchers discovered that sphingosine is a necessary co-factor for NAADP-mediated calcium release through TPCs. By trapping sphingosine inside the lysosome via LIMP-2 inhibition, Tetrandrine effectively "locks" the TPC channels, preventing the calcium signaling that viruses like Ebola exploit for cell entry. This signaling could be fully restored by exogenous addition of sphingosine, proving that the calcium block is a secondary effect of lipid transport disruption.
Dose-Dependent Effects and Apoptosis
The study also clarified Tetrandrine's anti-tumor mechanism. While low doses specifically target LIMP-2 to modulate calcium, higher doses trigger the Unfolded Protein Response (UPR) and lead to apoptosis. Interestingly, this high-dose apoptotic effect was found to be independent of LIMP-2, suggesting that Tetrandrine may have secondary targets involved in protein homeostasis at higher concentrations.
Discussion and Conclusion
This research fundamentally shifts our understanding of Tetrandrine's pharmacology. Rather than being a direct channel blocker, Tetrandrine acts as a LIMP-2 inhibitor that modulates the lysosomal lipid environment. This discovery highlights the critical role of LIMP-2 and sphingosine in regulating endolysosomal calcium signaling.
While the binding affinity of Tet to LIMP-2 is in the micromolar range, the specificity of the mechanism provides a clear blueprint for developing more potent LIMP-2 inhibitors. Such compounds could serve as a new class of antiviral and anti-tumor therapeutics. Future work will focus on obtaining high-resolution structural data of the Tet-LIMP-2 complex and further exploring the LIMP-2-independent pathways activated at high drug concentrations.
Summary updated